U.S., April 24 -- ClinicalTrials.gov registry received information related to the study (NCT06940154) titled 'Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)' on April 03.
Brief Summary: This is a Phase 2, multicenter study in adult participants with an acute COPD exacerbation and type 2 inflammation
Study Start Date: May, 2025
Study Type: INTERVENTIONAL
Condition:
COPD Acute Exacerbation
Intervention:
COMBINATION_PRODUCT: Rademikibart in prefilled syringe
Participants receive 600 mg (4mL) of rademikibart administered subcutaneously.
DRUG: Matching placebo in prefilled syringe
Participants receive 4mL of placebo matched to rademikibart administered subcutaneously.
Recruitment Status: NOT_YET_RECR...